Shots:

• The approval was granted based on the data from the P-III (ADVANCE-CIDP 2) trial evaluating the safety & efficacy of GAMMAGARD LIQUID in patients (n=18) with CIDP who developed a relapse in the P-III (ADVANCE-CIDP 1) trial assessing the safety, efficacy & tolerability of Hyqvia 
• As per the results, the responder rate depicting the efficacy of GAMMAGARD LIQUID was 94.4% as the INCAT score returned to baseline values before joining in 94.4% of the patients at 6mos.
• GAMMAGARD LIQUID is an intravenous IVIG approved as an IG therapy for CIDP patients, as a replacement therapy for primary immunodeficiency in adult & pediatric patients & as a maintenance therapy for multifocal motor neuropathy (MMN)

Ref: Takeda | Image: Takeda

Related News:- Takeda’s Hyqvia Receives the US FDA Approval as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com